Category: ARC News

Tegsedi approval granted
Tegsedi (Inotersen) approved by FDA for hATTR amyloidosis
The U.S. Food and Drug Administration today approved Tegsedi (inotersen), a novel therapy for the treatment of hereditary TTR amyloidosis polyneuropathy. (more…)
Read More
cardiac amyloid is often misdiagnosed.
Cardiac Amyloid takes center stage at HFSA
For many years, cardiac amyloid has had a few remarkable champions, preaching to half-empty rooms at medical conferences. Well, all that has changed. (more…)
Read More
Global Genes honoros Isabelle Lousada
ARC CEO Named 2018 Rare Champion of Hope
Earlier this month, ARC CEO, Isabelle Lousada was among a small group of honorees named 2018 RARE Champion of Hope award recipients by Global Genes. (more…)
Read More
Amyloidosis suppor
FDA approves first treatment for hereditary ATTR amyloidosis
The U.S. Food and Drug Administration today approved Patisiran, a novel therapy for the treatment of hereditary ATTR amyloidosis polyneuropathy. (more…)
Read More
New hATTR Treatments Under Review for their ‘Value for Money’
Two vitally important reviews are underway for patisiran and inotersen, new treatments that have been trialed for hATTR patients. One review is led by the National Institute for Health and Clinical Excellence (NICE) in the UK. (more…)
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
22 (G1) FORTH STREET, EDINBURGH, UK EH1 3LH | +44 (0) 131 550 3866
arc@arci.org

ARC is a 501(c)(3) nonprofit organization